MOTS-c: Sourcing, Purity, and Verification Standards

Introduction

This article covers the sourcing, synthesis, purity standards, and verification processes SpartaLabs applies to MOTS-c for research-use supply. The quality of research compounds has a direct bearing on the reproducibility and interpretability of experimental findings—impure or mischaracterized material generates noise rather than signal in research settings. Researchers working with MOTS-c can find below a description of how the compound is manufactured, how purity is established and independently confirmed, and what information is provided in the batch documentation accompanying each supply. Current batch documentation and ordering information is available on the MOTS-c product page.

Synthesis and Manufacturing

MOTS-c (amino acid sequence MRWQEMGYIFYPRKLR) is a 16-amino-acid linear peptide with a molecular weight of approximately 2,174.6 g/mol. Peptides of this size and sequence complexity are produced by solid-phase peptide synthesis (SPPS), the method developed by R. Bruce Merrifield and recognized with the Nobel Prize in Chemistry in 1984 [1]. SPPS allows sequential assembly of the peptide chain on a solid resin support, with each amino acid coupled in a defined order using protected building blocks. After chain assembly, the peptide is cleaved from the resin and global protecting groups are removed, yielding the crude linear peptide.

Crude MOTS-c is then subjected to preparative high-performance liquid chromatography (HPLC) purification to separate the target sequence from truncated sequences, deletion impurities, and synthesis by-products [2]. The purified material is lyophilized—freeze-dried from a defined solvent system—to produce a stable powder for long-term storage. Modern SPPS facilities operating under quality-controlled conditions routinely achieve research-grade purity for peptides of MOTS-c's length and complexity. SpartaLabs sources MOTS-c from GMP-aligned synthesis facilities with documented quality management systems.

Purity Standards

Analytical purity for research-grade peptides is established primarily by reversed-phase HPLC, which resolves the target compound from impurities based on hydrophobicity. HPLC purity is expressed as the area percentage of the main peak relative to all detected peaks at the monitored wavelength (typically 214 nm or 220 nm, corresponding to peptide bond absorbance). The industry standard for research-use peptide compounds is HPLC purity of ≥98%. SpartaLabs holds its MOTS-c supply to an internal standard of HPLC ≥98%.

Mass spectrometry (MS) confirmation—typically electrospray ionization or matrix-assisted laser desorption/ionization—establishes that the measured molecular weight of the compound matches the theoretical molecular weight calculated from the peptide sequence [2]. For MOTS-c, the expected average molecular weight is approximately 2,174.6 Da; confirmation of this value by MS provides independent evidence that the correct sequence was synthesized and is present in the sample.

Residual analysis covers counter-ions and solvent residuals arising from the synthesis and purification process. Trifluoroacetic acid (TFA), used as a mobile phase modifier in HPLC purification and in cleavage steps, can remain as a TFA salt if not exchanged. For sensitive applications, suppliers may offer an acetic acid salt or lyophilized-from-water form to reduce TFA content. Residual organic solvents (acetonitrile, DMF, NMP) are monitored against applicable international pharmaceutical guidelines even for research-use material, as residuals can introduce confounds in cell culture experiments [3]. Endotoxin (lipopolysaccharide) testing is applied to batches intended for cell-based or in vivo research applications.

Third-Party Verification

Third-party analytical testing is a cornerstone of research-compound quality assurance. When an independent laboratory—with no commercial relationship to the manufacturer—performs HPLC and mass spectrometry analysis on a sample drawn from the commercial batch, the results are not subject to the same potential conflicts of interest as manufacturer-generated data. Published analyses of commercially sourced research peptides have documented significant quality variability across suppliers, including misidentified sequences and purity values substantially below label claims [4].

SpartaLabs submits each MOTS-c batch to an independent third-party laboratory for HPLC purity analysis and mass spectrometry confirmation before release. The results are incorporated into the batch Certificate of Analysis (COA), which documents both the manufacturer's analytical data and the independent verification outcomes. Research integrity depends on the reliability of the materials used; third-party verification is SpartaLabs's mechanism for ensuring that what is labeled is what is supplied.

Certificates of Analysis

A SpartaLabs Certificate of Analysis for MOTS-c includes the following information for each batch:

• HPLC purity: percentage area of the main peak in reversed-phase HPLC, with chromatogram
• Mass spectrometry confirmation: measured molecular weight versus theoretical molecular weight, with spectrum
• Batch number: unique identifier linking the document to the manufacturing record
• Manufacturing date and expiry date: shelf-life documentation for proper inventory management
• Storage conditions: conditions under which the batch was held between manufacture and dispatch

The COA is available on each product page and can be requested directly for any batch by referencing the batch number. Researchers are encouraged to retain the COA as part of their experimental records—including the document in supplementary material or methods sections provides a verifiable chain of evidence for the material used.

Storage and Stability

Lyophilized MOTS-c powder is stable for extended periods when stored appropriately. Published stability data on synthetic peptide powders support storage at −20 °C or below for periods of one year or longer for most sequences, with stability further extended by protection from light and moisture [5]. Repeated freeze-thaw cycling of lyophilized material is not recommended; aliquoting before initial use and storing aliquots separately minimizes freeze-thaw exposure.

Once reconstituted in aqueous solution (typically sterile water, PBS, or a dilute acetic acid solution, per individual research protocol requirements), MOTS-c should be used promptly or stored as frozen aliquots at −80 °C. Reconstituted peptides in aqueous solution are subject to hydrolysis, oxidation, and aggregation at rates that depend on pH, temperature, and peptide-specific sequence characteristics; the relatively short chain length and basic character of MOTS-c (due to its Arg and Lys residues) are factors relevant to reconstitution stability. Researchers should refer to applicable literature for sequence-specific reconstitution guidance in their experimental system.

Why Sourcing Matters for Research

The integrity of any finding from MOTS-c research depends directly on the integrity of the compound used. Quality control failures in the research-peptide supply chain have produced misleading findings in the published literature, including cases where impure or mislabeled compounds generated experimental results that could not be replicated when correctly characterized material was substituted [4]. Batch-to-batch variability in purity and identity, when uncontrolled, introduces a systematic source of irreproducibility that is difficult to detect retrospectively.

SpartaLabs's quality posture—HPLC-verified purity, mass-spectrometry-confirmed identity, and independent third-party verification with published COA documentation—is designed to remove material quality as a variable in research design. Research-grade material from a verified-quality source enables reproducible research; that is the standard SpartaLabs holds itself to for every batch released for researcher use. Researchers also working with other mitochondrial cluster compounds may find the SS-31 sourcing and quality article useful, as it covers comparable SPPS and verification standards for that peptide.

References

1. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963 Jul;85(14):2149–2154. doi: 10.1021/ja00897a025.

2. Andersson L, Blomberg L, Flegel M, Lepsa L, Nilsson B, Verlander M. Large-scale synthesis of peptides. Biopolymers. 2000;55(3):227–250. doi: 10.1002/1097-0282(2000)55:3<227::AID-BIP50>3.0.CO;2-7. PMID: 10880970. https://pubmed.ncbi.nlm.nih.gov/10880970/

3. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q3C(R8): Guideline for residual solvents. 2021. https://www.ich.org/page/quality-guidelines

4. Melancon JM, Cormier J, Harber G, Wagner G, Teeple G, Rowe C, Watson R, Davis CB, Williams KL. Quality assessment of a selection of research-grade peptides commonly used in biological experiments. PLoS One. 2020 Jul 29;15(7):e0235421. doi: 10.1371/journal.pone.0235421. PMID: 32726317. https://pubmed.ncbi.nlm.nih.gov/32726317/

5. Otvos L Jr, Wade JD. Current challenges in peptide-based drug discovery. Front Chem. 2014 Dec 17;2:62. doi: 10.3389/fchem.2014.00062. PMID: 25566519. https://pubmed.ncbi.nlm.nih.gov/25566519/